

## Summary of Utilization Management (UM) Program Changes

August 2023

Brand Name	Generic Name	Utilization Update Summary	Type	Effective Date
<i>Praluent</i> <i>Repatha</i> in PCSK9 Inhibitors	alirocumab evolocumab	<p>Guideline was updated to align with 2022 American College of Cardiology consensus pathway for LDL-cholesterol lowering (nonstatin therapies).</p> <p>Diagnosis was simplified to untreated/pretreatment LDL-cholesterol greater than 190 mg/dL or confirmed atherosclerotic cardiovascular disease. The goal of LDL-cholesterol is stratified based on LDL-cholesterol number and history of cardiac events and high-risk conditions for future cardiac events.</p>	update	10/1/2023